Standard cardiovascular risk assessment may be fundamentally flawed for half the population. Despite women typically developing less arterial plaque buildup than men at comparable ages, they experience disproportionately severe cardiac complications when high-risk features appear on imaging studies. This paradox reveals critical blind spots in how medicine understands and treats heart disease across biological sexes. The evidence demonstrates that diabetes and smoking amplify cardiovascular danger more dramatically in women than men, while female-specific risk factors remain largely overlooked in clinical practice. Women face elevated cardiac threats from pregnancy complications, polycystic ovary syndrome, early menopause, and autoimmune conditions—yet these factors rarely influence standard risk calculations. Perhaps most concerning, women frequently suffer heart attacks and ischemic events despite having non-obstructive coronary arteries, a phenomenon that challenges conventional diagnostic frameworks focused on detecting large blockages. The medical establishment compounds these biological differences through treatment disparities. Women receive lipid-lowering medications and other preventive cardiac therapies at significantly lower rates than men, even when their risk profiles warrant aggressive intervention. This systematic under-treatment occurs alongside diagnostic approaches that may miss the subtler but equally dangerous patterns of atherosclerosis that characterize female cardiovascular disease. These findings suggest that personalized cardiac care requires sex-specific risk algorithms and treatment protocols. The traditional male-centric model of atherosclerosis—focused on large, obstructive plaques—may be inadequate for protecting women from cardiac events that arise through different pathophysiological mechanisms.